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Abstract 19 
The regulation of intracellular Ca
2+
 signaling is an important aspect of how anti-apoptotic B-cell 20 
lymphoma 2 (Bcl-2) proteins regulate cell death and cell survival. At the endoplasmic reticulum (ER) 21 
the Bcl-2 homology (BH) 4 domain of Bcl-2 is known to bind to and inhibit both inositol 1,4,5-22 
trisphosphate receptors (IP3Rs) and ryanodine receptors (RyRs). Besides this, drugs that target the 23 
hydrophobic cleft of Bcl-2 have been reported to deplete ER Ca
2+
 stores in an IP3R- and RyR- 24 
dependent way. This suggests that the hydrophobic cleft of Bcl-2 may also be involved in regulating 25 
these ER-located Ca
2+
-release channels. However, the contribution of the hydrophobic cleft on the 26 
binding and regulatory properties of Bcl-2 to either IP3Rs or RyRs has until now not been studied. 27 
Here, the importance of the hydrophobic cleft of Bcl-2 in binding to and inhibiting the RyR was 28 
assessed by using a genetic approach based on site-directed mutagenesis of Bcl-2’s hydrophobic cleft 29 
and a pharmacological approach based on the selective Bcl-2 hydrophobic cleft inhibitor, ABT-199. 30 
Both binding assays and single-cell Ca
2+
 measurements indicated that RyR binding and the inhibition 31 
of RyR-mediated Ca
2+
 release by Bcl-2 is independent of its hydrophobic cleft. 32 
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protein interaction trap (MAPPIT), ryanodine receptor (RyR), sarco-endoplasmic reticulum Ca
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 38 
ATPase (SERCA) 39 
Highlights 40 
 Bcl-2’s hydrophobic cleft is not involved in binding to and regulating RyRs 41 
 The BH3 mimetic ABT-199 does not alter Bcl-2’s ability to regulate RyRs 42 
 Bcl-2-P2A-mCherry can efficiently be used in single-cell Ca2+ measurements  43 
Introduction 44 
The modulation of intracellular Ca
2+
 signalling is an important aspect of how proteins of the B-cell 45 
lymphoma 2 (Bcl-2)-family regulate cell death and cell survival [1, 2, 3, 4]. The three C-terminally 46 
located Bcl-2 homology (BH) domains (BH1, BH2 and BH3) of anti-apoptotic Bcl-2 family members 47 
(such as Bcl-2 and Bcl-XL) form a hydrophobic cleft, which is used to bind to the BH3 domains 48 
present in the pro-apoptotic Bcl-2-family members, thereby inhibiting their function [5].  The N-49 
terminally located BH4 domain also critically determines its anti-apoptotic function in at least two 50 
ways: (i) by binding to and inhibiting the pro-apoptotic, multi-domain protein Bcl-2-associated X 51 
protein (Bax), which upon activation oligomerizes and permeabilizes mitochondrial outer membranes 52 
[6], and (ii) by binding to and inhibiting the inositol 1,4,5-trisphosphate (IP3) receptor (IP3R), an 53 
endoplasmic reticulum (ER)-located Ca
2+
-release channel, thereby preventing mitochondrial Ca
2+
 54 
overload [7].  55 
 We recently showed that, similarly to IP3Rs, anti-apoptotic Bcl-2 via its BH4 domain also targets 56 
another important ER-located family of Ca
2+
-release channels: the ryanodine receptors (RyRs) [8]. 57 
The BH4 domain of Bcl-2 was sufficient to interact with and suppress RyR-mediated Ca
2+
 release. For 58 
Bcl-XL the situation was different. In contrast to the IP3R, where the BH4 domain of Bcl-XL does not 59 
bind to and inhibit the channel [9], the BH4 domain of Bcl-XL is able to bind to and inhibit RyRs [10]. 60 
However, in the full-length Bcl-XL Lys87 located in the BH3 domain, which is part of the 61 
hydrophobic cleft, also plays a role in targeting Bcl-XL to the RyR. This suggests that the hydrophobic 62 
cleft of the anti-apoptotic Bcl-2 proteins may also play a role in targeting them to the RyR. In addition 63 
to this, drugs that target the hydrophobic cleft of Bcl-2 and thus compete with pro-apoptotic Bcl-2 64 
family members have been reported to deplete the ER Ca
2+
 stores in pancreatic acinar cells [11]. As 65 
these cells express both IP3Rs and RyRs [12], it was suggested that dissociation of the pro-apoptotic 66 
Bcl-2 family members from the anti-apoptotic family members by these Bcl-2 antagonists may 67 
increase the sensitivity of the IP3R and RyR to Ca
2+
-induced Ca
2+
 release [11]. However, it was not 68 
investigated whether these compounds effectively altered the binding of Bcl-2 to either of these ER-69 
located Ca
2+
-release channels. Furthermore, the Bcl-2 antagonists used in this study are not selective 70 
Bcl-2 inhibitors, thereby affecting other proteins. For instance, the Bcl-2 antagonist HA14-1 also 71 
inhibits the activity of the sarco-/endoplasmic reticulum Ca
2+
 ATPase (SERCA), thereby causing ER 72 
Ca
2+
-store depletion [13, 14].  73 
Therefore, we here assessed the involvement of the hydrophobic cleft of Bcl-2 in binding to and 74 
inhibiting the RyR by using both site-directed mutagenesis and a novel specific Bcl-2 inhibitor, ABT-75 
199. This analysis shows that RyR binding and inhibition by Bcl-2 is independent of its hydrophobic 76 
cleft properties.   77 
Materials and methods 78 
Chemicals, antibodies and peptides 79 
Unless otherwise mentioned all chemicals were obtained from Sigma-Aldrich. The antibodies used in 80 
this study include: HRP conjugated anti-FLAG M2 antibody (Sigma-Aldrich), mouse monoclonal 81 
anti-RyR antibody 34C (Thermo Scientific, Rockford, IL, USA, or Developmental Studies Hybridoma 82 
Bank, University of Iowa, USA) and rabbit polyclonal anti-Bax (Santa Cruz). The peptide used for 83 
elution of the FLAG pull-downs was MDYKDHDGDYKDHDIDYKDDDDK (Life Tein). 84 
 85 
Plasmids and constructs 86 
The used restriction enzymes were obtained from New England BioLabs. 3XFLAG-tagged Bcl-2 87 
(3XFLAG-Bcl-2) was obtained as described previously [9]. PCR site-directed mutagenesis using the 88 
3XFLAG-Bcl-2 construct as template (primers forward: 89 
5’ATCCCCATGGCAGCAGTAGATCAAGCGCTGAGGGAGGCA3’, and reverse: 90 
5’TGCCTCCCTCAGCGCTTGATCTACTGCTGCCATGGGGAT3’) was performed to obtain the 91 
3XFLAG-Bcl-2 G145A R146A (3XFLAG-Bcl-2
GR/AA
) double mutant. The pCMV24 vector encoding 92 
the P2A-mCherry or 3XFLAG-Bcl-2-P2A-mCherry were obtained as follows. A P2A-encoding DNA 93 
sequence (corresponding to amino acid sequence GSGATNFSLLKQAGDVEENPGP) [15] was 94 
obtained as a duplex with overhanging ends corresponding to cleaved EcoRI and BglII restriction sites 95 
forward: 96 
5’AATTCGGATCCGGAGCCACGAACTTCTCTCTGTTAAAGCAAGCAGGAGACGTGGAAGA97 
AAACCCTGGTCCTA3’, and reverse 98 
5’GATCTAGGACCAGGGTTTTCTTCCACGTCTCCTGCTTGCTTTAACAGAGAGAAGTTCGT99 
GGCTCCGGATCCG3’. The duplex was ligated into the empty pCMV24 vector utilizing EcoRI and 100 
BglII as restriction sites. After removing the BglII site from the mCherry construct via site-directed 101 
mutagenesis (primers forward: 5’GGACGAGCTGTACAAGAGGTCTCGAATCACAAGTTTG3’, 102 
and reverse: 5’ CAAACTTGTGATTCGAGACCTCTTGTACAGCTCGTCC3’), mCherry was cloned 103 
at the 3’ side of the P2A sequence (primers forward: 104 
5’GCGGCGAGATCTGTGAGCAAGGGCGAGGAGGAC3’, and reverse: 105 
5’GCGGCGGTCGACTTACGTTTCTCGTTCAGC3’) utilizing the BglII and SalI restriction 106 
enzymes. At the 5’ side of the P2A sequence, Bcl-2 was cloned (primers forward: 107 
5’GCGGCGGCGGCCGCAGCGCACGCTGGGAGAAC3’, and reverse: 108 
5’GCGGCGGAATTCCTTGTGGCCCAGATAGGCAC3’) utilizing the NotI and EcoRI restriction 109 
enzymes and the 3XFLAG-Bcl-2 plasmid as template. One nucleotide was added just before the 110 
multiple cloning site in order to put the pCMV24-P2A-mCherry construct in the correct open reading 111 
frame (primers forward: 5’GGATGACGATGAGCAAGCTTGCGGC3’, and reverse: 112 
5’GCCGCAAGCTTGCTCATCGTCATCC3’). 113 
 114 
Cell culture and transfections  115 
All media used in this study were obtained from Life Technologies. HEK293T cells, and HEK293 116 
cells stably overexpressing RyR3 (HEK RyR3) were cultured as previously [10].  117 
One day after seeding, the 3XFLAG-Bcl-2 or 3XFLAG-Bcl-2
GR/AA
 construct were introduced into 118 
HEK RyR3 cells utilizing the X-tremeGENE HP DNA transfection reagent (Roche) according to the 119 
manufacturer’s protocol. For single-cell Ca2+ measurements two different methods for introducing 120 
mCherry, as selection marker for transfected cells, into the cells were used. First, 48 hours after 121 
seeding the pCMV24 vector (negative control), 3XFLAG-Bcl-2 or the 3XFLAG-Bcl-2
GR/AA
 construct 122 
were transfected together with a pcDNA 3.1(-) mCherry expressing vector as a selection marker at a 123 
3:1 ratio as previously described [10]. Second, 48 hours after seeding, 0.25 µg of a pCMV24 vector 124 
encoding the P2A-mCherry or a pCMV24 vector encoding 3XFLAG-Bcl-2-P2A-mCherry was 125 
introduced into the HEK RyR3 cells utilizing the X-tremeGENE HP DNA transfection reagent. All 126 
single-cell Ca
2+
 measurements were performed two days after the transfection. 127 
 128 
Co-immunoprecipitations, FLAG pull-downs and immunoblots 129 
Co-immunoprecipitation experiments were performed utilizing a co-immunoprecipitation kit (Thermo 130 
Scientific) in HEK RyR3 cells as described previously [10]. The negative control IgG was obtained 131 
from Thermo Scientific. Cell lysis and wash steps were performed with a CHAPS-based buffer (50 132 
mM Tris-HCl pH 7.5, 100 mM NaCl, 2 mM EDTA, 50 mM NaF, 1 mM Na3VO4, 1% CHAPS and 133 
protease inhibitor tablets (Roche)). When indicated, 3 µM of ABT-199 (Active Biochem) was added 134 
during the overnight incubation. In the control co-immunoprecipitations an equal amount of the 135 
vehicle (DMSO) was included. For FLAG pull-downs, 300 µg of HEK RyR3 cells transfected with the 136 
empty vector, 3XFLAG-Bcl-2 or 3XFLAG-Bcl-2
GR/AA
 were lysed (10 mM HEPES pH 7.5, 0.25 % 137 
Nonidet P-40, 142 mM KCl, 5 mM MgCl2, 2 mM EDTA, 1 mM EGTA and protease inhibitor tablets) 138 
and incubated for 2 hours at 4°C with 30 µl of anti-DYKDDDDK (L5)–tag agarose (Biolegend). After 139 
extensive washing (50 mM Tris pH 8, 150 mM NaCl, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% 140 
sodium dodecyl sulfate, and protease inhibitor tablets) elution was performed by incubating the resin 141 
for 30 min at 15°C with FLAG elution peptide (250 µg/ml 50 mM Tris-HCl pH 7.4, 150 mM NaCl). 142 
After the elution, the eluate was collected and 4X LDS (Life Technologies) supplemented with 1/200 143 
β-mercaptoethanol. Samples were boiled (95°C) for 5 min just before SDS-PAGE on either NuPAGE 144 
4-12% Bis-Tris gels or NuPAGE 3-8% Tris-Acetate gels (both from Life Technologies) when 145 
RyRs were visualized. gels. Immunoblot analysis was performed as previously [10]. 146 
 147 
Mammalian protein-protein interaction trap (MAPPIT) 148 
Bcl-2-associated death promoter  (Bad), and Bcl-2 were cloned in the pSEL+2L bait vector, TRIP13 149 
and Bcl-2 lacking its transmembrane domain were cloned in the pMG1 or pMG2 prey vector, 150 
respectively [16]. Bad and TRIP13 entry clones are from the ORFeome8.1 collection received from 151 
the Vidal lab (CCSB, Boston, USA), and were cloned as bait or prey, respectively using the Gateway 152 
recombination technology as described by the manufacturer (Life Technologies). Using the pCAGGS-153 
Bcl-2 plasmid, obtained from BCCM/LMBP (Gent, Belgium) as template, Bcl-2 was amplified by 154 
PCR using the following primers, forward: 5’GCGGAATTCATGGCGCACGCTGGGAGA3’, and 155 
reverse: 5‘CGCGCGGCCGCTCACTTGTGGCCCAGATAGG3’, and was cloned in the pMG2 prey 156 
vector using the restriction enzymes EcoRI and NotI. Bcl-2 was cloned in the bait vector, by EcoRI 157 
digestion of the above described Bcl-2 prey vector, made blunt by nucleotide fill-in, and followed by a 158 
NotI restriction digest, and SalI digestion of the pSEL+2L bait vector, made blunt by nucleotide fill-in 159 
and subsequent NotI digestion. The Bcl2 prey lacking its transmembrane domain was obtained by 160 
PCR amplification on the Bcl-2 prey construct using the same forward primer as described above and 161 
the following reverse primer: 5’CGCGCGGCCGCTCAGGAGAAATCAAACAGAGGCC3’, and was 162 
cloned in the pMG2 prey vector using the restriction enzymes EcoRI and NotI.  163 
MAPPIT experiments were performed as previously [10], with minor changes. Briefly, HEK293T 164 
cells were seeded in 96-well plates. Six wells per condition were transfected with the different 165 
combinations of bait, prey and reporter plasmid (rPAP1-luci) using the calcium phosphate method. 166 
The next day, a serial dilution of the ABT-199 compound was added and 4 hours later half of the wells 167 
were stimulated with 5 ng/ml erythropoietin (Epo) while the other half were left untreated. One day 168 
later the cells were lysed and after the addition of substrate the luciferase activity was determined 169 
using a luminometer. The fold induction was obtained by dividing the average value of the stimulated 170 
cells by the average value of the non-stimulated cells.  171 
 172 
Single-cell Ca
2+
 measurements and fluorescence microscopy 173 
Single-cell Ca
2+
 measurements were performed as previously [8]. mCherry was used as selection 174 
marker for the transfected cells. When used, ABT-199 or an equal volume of the vehicle (DMSO) was 175 
included during the loading and de-esterification (1 hour in total) of the Fura2-AM in the HEK RyR3 176 
cells. A Zeiss Axio Observer Z1 Inverted Microscope equipped with a 20x air objective and a high-177 
speed digital camera (Axiocam Hsm, Zeiss) was used for imaging mCherry expression. 178 
 179 
Statistical analysis 180 
Repeated measure ANOVA tests were performed. * indicates significantly different results (p<0.05). 181 
Exact p-values are indicated in the figure legends. NS indicates non-significant.  182 
Results and discussion 183 
The hydrophobic cleft of Bcl-2 has been extensively characterized with respect to its binding to BH3 184 
domains of the pro-apoptotic Bcl-2 family members. Mutations disrupting the hydrophobic cleft of 185 
Bcl-2 and thereby abolishing binding of Bcl-2 to Bax and Bcl-2 homologous antagonist killer (Bak) 186 
have been described [17]. Using a Bcl-2 hydrophobic cleft double mutant (G145A and R146A (Bcl-187 
2
GR/AA
)), we aimed to elucidate whether or not this region is involved in regulating RyRs. 188 
We first validated that the Bcl-2
GR/AA
 mutant was unable to bind the pro-apoptotic protein Bax by 189 
performing FLAG-pull-down assays in HEK RyR3 cells transiently overexpressing the empty vector 190 
(pCMV24), 3XFLAG-Bcl-2 or the 3XFLAG-Bcl-2
GR/AA
 mutant (Fig. 1A). The 3XFLAG-tagged 191 
constructs were pulled down (Fig 1A, top) after which the presence of endogenous Bax was assessed. 192 
Bax specifically co-immunoprecipitated with 3XFLAG-Bcl-2, while it was absent in empty vector 193 
control samples. Furthermore, in contrast to wild-type 3XFLAG-Bcl-2 the 3XFLAG-Bcl-2
GR/AA
 194 
mutant could not pull-down endogenous Bax (Fig. 1A, bottom), indicating that these mutations disrupt 195 
the hydrophobic cleft as reported. Next, co-immunoprecipitation experiments were set up in order to 196 
verify whether the hydrophobic cleft of Bcl-2 is involved in binding to RyR3. RyR3 was 197 
immunoprecipitated from HEK RyR3 cells (Fig. 1B, top) transiently overexpressing 3XFLAG-Bcl-2 198 
or 3XFLAG-Bcl-2
GR/AA
. Strikingly, mutating the hydrophobic cleft of Bcl-2 resulted in an increased 199 
binding to RyR3 (Fig. 1B, bottom). This might indicate that more of 3XFLAG-Bcl-2
GR/AA
 may be 200 
available to bind to RyR3 due to its impaired recruitment to pro-apoptotic Bcl-2-family members.  201 
Finally, Fura2-AM single-cell Ca
2+
 measurements were set up to assess whether disruption of Bcl-2’s 202 
hydrophobic cleft affected its ability to inhibit RyR3-mediated Ca
2+
 release. In these experiments, the 203 
empty vector (pCMV24), 3XFLAG-Bcl-2 or the 3XFLAG-Bcl-2
GR/AA
 mutant were transfected in HEK 204 
RyR3 cells at a 3:1 ratio with mCherry. Only mCherry-positive cells were included in these 205 
measurements. RyR-mediated Ca
2+
 release was evoked with caffeine (1.5 mM) after chelating 206 
extracellular Ca
2+
 with BAPTA (3 mM). An average Ca
2+
 trace of a typical experiment is shown in 207 
Fig. 2A whereas the summary of all performed Ca
2+
 measurements is presented in Fig. 2B. From this it 208 
was clear that, Bcl-2 mutations that disrupt the hydrophobic cleft did not affect the ability of Bcl-2 to 209 
inhibit RyR3. This suggests that the hydrophobic cleft of Bcl-2 is not involved in targeting RyR3. 210 
To further substantiate our findings, an independent pharmacological approach was performed, 211 
utilizing a BH3-mimetic drug which occupies the hydrophobic cleft of Bcl-2. In recent years, several 212 
advances have been made in generating highly specific BH3-mimetic drugs [18]. One of the most 213 
recent compounds, ABT-199, was designed to have a high specificity for Bcl-2 over Bcl-XL thereby 214 
limiting side effects generated by unwanted Bcl-XL inhibition [18]. In this study we used this ABT-215 
199 compound in order to independently assess the importance of the hydrophobic cleft of Bcl-2 for 216 
RyR interaction and regulation by Bcl-2. 217 
First, we assessed the efficiency of the compound in disrupting the binding of Bcl-2 to the pro-218 
apoptotic Bcl-2 family members. For this we utilized an in cellulo protein-protein interaction assay, 219 
MAPPIT [10, 19]. In this technique, functional complementation of a chimeric cytokine receptor 220 
serves as a read out for the binding of two proteins. The first binding partner , Bad (bait) was fused to 221 
the membrane bound chimeric cytokine receptor consisting of the extracellular domain of the Epo 222 
receptor fused to the transmembrane and mutated cytosolic part of the leptin receptor. The second 223 
binding partner, Bcl-2 lacking its transmembrane domain (prey) was fused to a part of the glycoprotein 224 
130 receptor which can trigger Epo-dependent STAT signaling when binding to the bait occurs. The 225 
latter is monitored via a luciferase reporter assay driven by a STAT-sensitive promoter. As expected, 226 
Bad could bind to Bcl-2 which could be inhibited by ABT-199 in a concentration-dependent way 227 
(EC50~20 nM) (Fig 3A). A positive control, consisting of Bcl-2 as bait and TRIP13 as prey, which 228 
triggers STAT signaling independently from binding to the bait, showed no decreased binding in the 229 
presence of ABT-199 indicating that the compound disrupts the Bad/Bcl-2 interaction specifically. 230 
Next, we wanted to assess the effect of ABT-199 on the binding of Bcl-2 to full size RyR3. For this, 231 
similar co-immunoprecipitations as in Fig. 1B were set up. In the next experiments 3 µM of ABT-199 232 
was used as this concentration was  more than sufficient to completely disrupt binding of Bad and Bcl-233 
2 and we wanted to maximize the possible effects of the compound on the RyR/Bcl-2 interaction. 234 
RyR3 was immunoprecipitated from lysates from HEK RyR3 cells overexpressing 3XFLAG-Bcl-2 235 
after overnight incubation with ABT-199 or the vehicle (DMSO) (Fig. 3B, top). Similar amounts of 236 
3XFLAG-Bcl-2 could be co-immunoprecipitated under these two conditions (Fig. 3B, bottom) 237 
underpinning the data obtained with the Bcl-2 hydrophobic cleft mutant (Fig. 1B).  238 
Next, we assessed the effect of the ABT-199 compound on the ability of Bcl-2 to inhibit RyR-239 
mediated Ca
2+
 release. For this we optimized the use of a different plasmid combining the 3XFLAG-240 
Bcl-2 construct with the mCherry selection marker in the same vector. The previously described virus-241 
derived P2A sequence was used for this purpose [15]. This sequence, once translated, is known to 242 
cleave itself without any involvement of the host cell. The P2A sequence was introduced in the 243 
pCMV24 vector flanked on its N-terminus by 3XFLAG-Bcl-2 and at the C-terminus by mCherry 244 
(3XFLAG-Bcl-2-P2A-mCherry). A pCMV24 vector encoding P2A-mCherry was also made as 245 
control. Before proceeding we verified whether the P2A sequence produced two separate proteins. 246 
First, lysates from HEK RyR3 cells expressing either 3XFLAG-Bcl-2-P2A-mCherry or 3XFLAG-Bcl-247 
2 were immunoblotted. These showed in both cells the presence of 3XFLAG-Bcl-2 (Fig. 4A). In the 248 
3XFLAG-Bcl-2-P2A-mCherry expressing cells this migrated at a slightly higher molecular mass 249 
because part of the P2A sequence remains attached to the protein preceding the P2A sequence. As 250 
reported previously, a weaker second product was also recognized at a slightly lower molecular mass 251 
[15, 20]. Since this is also recognized by the anti-FLAG antibody, this is likely also 3XFLAG-tagged-252 
Bcl-2 protein lacking the P2A sequence. This band migrates slightly lower than the 3XFLAG-Bcl-2 253 
next to it because the Myc-tag, present at the C-terminal end of the multiple cloning site of the 254 
pCMV24 vector, is in this case attached to the mCherry protein and not to the 3XFLAG-Bcl-2. 255 
Importantly, no FLAG-reactive signal could be detected at higher molecular weights. Since the 256 
3XFLAG tag allows for a very sensitive detection, this result indicates that the vast majority of the 257 
P2A-containing constructs was cleaved, resulting in the overexpression of two separate proteins. Next, 258 
the two transfection protocols for single-cell Ca
2+
 measurements utilized in present study were 259 
compared for their mCherry expression (Fig. 4B). Both methods resulted in a similar number of 260 
mCherry-positive cells, indicating that the P2A-containing constructs can be used as selection marker 261 
in the single-cell Ca
2+
 measurements. Fura2-AM single-cell Ca
2+
 measurements were performed in 262 
HEK RyR3 cells overexpressing either P2A-mCherry as a control or 3XFLAG-Bcl-2-P2A-mCherry. 263 
During the loading and de-esterification steps (1 hour in total), ABT-199 (3 µM) or the vehicle control 264 
(DMSO) was added to the cells. The Ca
2+
 measurements were similarly performed as above. 265 
Introducing 3XFLAG-Bcl-2 into these HEK RyR3 cells via the 3XFLAG-Bcl-2-P2A-mCherry 266 
construct resulted in about 50% decrease in caffeine-induced Ca
2+
 release (Fig. 4 C, D). ABT-199 did 267 
not impact the ability of Bcl-2 to inhibit caffeine-induced RyR-mediated Ca
2+
 release. It should be 268 
noted that ABT-199 slightly and non-significantly reduced caffeine-induced Ca
2+
 release in control 269 
conditions, which may suggest a minor direct impact of these drugs on RyRs. 270 
The data obtained with the ABT-199 compound support the results using the Bcl-2 hydrophobic cleft 271 
mutant and suggest that the ABT-199 BH3 mimetics do not alter Bcl-2’s ability to inhibit RyRs 272 
thereby decreasing the risk of potential side effects of these drugs.   273 
In conclusion, disrupting the binding between the hydrophobic cleft of Bcl-2 and the pro-apoptotic 274 
family members, does not alter Bcl-2-mediated regulation of the RyR.   275 
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 332 
  333 
Figure legends 334 
Figure 1: Mutational disruption of the hydrophobic cleft of Bcl-2 does not disrupt Bcl-2/RyR 335 
complexes.  336 
(A) Immunoblot of FLAG pull-downs performed on lysates from HEK RyR3 cells transiently 337 
overexpressing the empty vector (pCMV24), 3XFLAG-Bcl-2 or the 3XFLAG-Bcl-2
GR/AA
 mutant. The 338 
FLAG-tagged proteins were pulled down using agarose coupled to a FLAG-recognizing antibody. The 339 
empty vector (pCMV24) was used as negative control. Immunoblots were stained with an anti-FLAG-340 
HRP-conjugated antibody (top) or an anti-Bax antibody (bottom). All experiments were performed 341 
independently at least three times. (B) Immunoblot of the performed co-immunoprecipitation 342 
experiments using HEK RyR3 lysates overexpressing 3XFLAG-Bcl-2 or the 3XFLAG-Bcl-2
GR/AA
 343 
mutant. RyR3 was immunoprecipitated using a RyR antibody recognizing all RyR isoforms (top). Co-344 
immunoprecipitations with non-specific IgG antibodies were used for every condition as negative 345 
control. The presence of the co-immunoprecipitated FLAG-tagged proteins was assessed with an anti-346 
FLAG HRP-conjugated antibody (bottom). The experiments were performed independently at least 347 
three times. For clarity reasons, a longer exposure of the input sample lanes obtained from the same 348 
gel/blot is shown. 349 
Figure 2: Mutational disruption of the hydrophobic cleft of Bcl-2 does not alter Bcl-2-mediated 350 
inhibition of RyR-mediated Ca
2+
 release. 351 
(A) Average calibrated trace (15-20 cells) of a typical single-cell Ca
2+
 measurement utilizing Fura-352 
2AM as Ca
2+
 indicator. The empty vector (pCMV24), 3XFLAG Bcl-2 or 3XFLAG-Bcl2
GR/AA
 was 353 
cotransfected with mCherry (3:1 ratio) to identify transfected cells. One minute after chelating 354 
extracellular Ca
2+
 with BAPTA (3 mM), caffeine was added (1.5 mM) as indicated by the arrows. (B) 355 
Summary of the performed single-cell Ca
2+
 measurement experiments. The data points indicate the 356 
average caffeine-induced Ca
2+
 release ([Ca
2+
]peak-[Ca
2+
]before caffeine) of all traces performed on the same 357 
day. All experiments were repeated three times independently and experiments performed on the same 358 
day are indicated by the same symbol in the same color (N>80 cells/condition). The average ±S.E.M. 359 
is indicated in gray (p=0.0091). 360 
Figure 3: The BH3 mimetic ABT-199 does not disrupt Bcl-2/RyR complexes. 361 
(A) A representative example of the performed MAPPIT experiments. The binding is shown as fold 362 
induction value, calculated by dividing the average luciferase activity of Epo-stimulated cells by the 363 
average of non-stimulated cells. Binding of the positive control or of Bad to Bcl-2 is shown in the 364 
presence of increasing concentrations of ABT-199. (B) Immunoblot of the performed co-365 
immunoprecipitation experiments in HEK RyR3 cells overexpressing 3XFLAG Bcl-2 as performed in 366 
Figure 1B (top). ABT-199 (3 µM) or an equal volume of DMSO was included during the overnight 367 
incubation step. Quantification of the performed experiments. Non-specific 3XFLAG-Bcl-2 binding to 368 
the corresponding negative control (IgG) was subtracted from the amount of 3XFLAG-Bcl-2 co-369 
immunoprecipitated with RyR3 and expressed relative to the DMSO control. Values depict average ± 370 
SD. Experiments were repeated three times independently (bottom).  371 
Figure 4: The BH3 mimetic ABT-199 does not alter Bcl-2-mediated inhibition of RyR-mediated 372 
Ca
2+
 release. 373 
(A) Immunoblot stained with anti-FLAG HRP-conjugated antibody of HEK RyR3 lysates transiently 374 
transfected with 3XFLAG-Bcl-2 or 3XFLAG-Bcl-2-P2A-mCherry. The * indicates a byproduct of the 375 
P2A cleavage process also recognized by the anti-FLAG antibody. (B) Fluorescence and bright field 376 
overlay image, comparing the mCherry signal after transfection with 3XFLAG-Bcl-2 at 3:1 ratio with 377 
mCherry (top) or the 3XFLAG-Bcl-2-P2A-mCherry construct (bottom). (C) Average calibrated trace 378 
(15-20 cells) of single cell Ca
2+
 measurements, performed as in Figure 2, in HEK RyR3 cells 379 
transfected with the pCMV24 containing P2A-mCherry (control) or the 3XFLAG-Bcl-2-P2A-380 
mCherry construct. ABT-199 (3 µM) or an equal volume of DMSO was added to the cells during the 381 
loading and de-esterification (one hour in total) of Fura2-AM. (D) Summary of the performed single-382 
cell Ca
2+
 measurements. Experiments performed during the same day are indicated by the same 383 
symbol and color. The data points indicate average caffeine-induced Ca
2+
 release ([Ca
2+
]peak-[Ca
2+
]before 384 
caffeine) of all traces performed on the same day. All experiments were performed three times 385 
independently (N>80 cells/condition). The average ±S.E.M. is indicated in gray (p=0.0015).  386 
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